Arm Holdings CEO Rene Haas said AI will find a cure for cancer within the next few decades by solving problems too complex for humans, such as modelling DNA markers impacted by cancer. Haas told the B…
Lloyd Armbrust and Emily Colman launched RonanRX, an AI-assisted care platform that uses patient data to help physicians personalize compounded GLP-1 doses, with its public launch as of September 2, 2…
AI companies including Anthropic, Nvidia, and Google's Isomorphic Labs are increasingly investing in health care and drug discovery to counter public backlash over data centers and job losses, with Nv…
RonanRx, an AI-assisted GLP-1 care platform founded by Lloyd Armbrust and Emily Colman, launched August 4th in Y Combinator's Summer 2026 batch, but its service currently operates only in Texas despit…
Chai Discovery, a San Francisco-based AI drug discovery company whose platform is used by Eli Lilly, Pfizer, and Novartis, is hiring a Scientist for Protein Design to work on-site with its science tea…
Big Pharma's second-quarter earnings calls highlighted the growing role of AI in drug development and the intensifying oral GLP-1 competition between Novo Nordisk and Eli Lilly, alongside leadership c…
Chai Discovery, a San Francisco-based company building AI models for biochemical structure and interaction, posted an internship listing despite stating it does not offer internships, inviting interes…
Amplia (ASX:ATX), a pancreatic cancer drug developer, has diversified its clinical program by partnering with Eli Lilly to combine its lead compound narmafotinib (AMP-945) with an Eli Lilly KRAS inhib…
Investor's Business Daily's screener for stocks that funds are buying shows a dozen names near buy points, including Hewlett Packard Enterprise (HPE), Coherent (COHR), Amphenol (APH), and Eli Lilly (L…
Nestle is using artificial intelligence and nutritional science to develop products for the millions of Americans taking GLP-1 weight-loss drugs such as Ozempic and Wegovy, aiming to turn the rise of …
Chai Discovery, a San Francisco-based biotech startup, released Chai-3, a generative AI model for molecular design that doubles the success rate of its predecessor in creating therapeutic antibodies, …
SpaceX (SPCX) will report its first earnings as a public company on Tuesday, with shares down nearly 30% from their $150 IPO debut last month. The July jobs report, due Friday, is expected to show 88,…
Isomorphic Labs, the Alphabet spinoff, released IsoDDE on February 10, a unified drug design engine that achieves a 50% success rate on the hardest molecular prediction tasks, outperforming AlphaFold …
Bristol Myers Squibb is expanding its partnership with Nvidia to boost AI computing power for drug discovery, building on its AI Center of Excellence using Nvidia's DGX SuperPOD infrastructure that ha…
Chai Discovery Inc. has raised $400 million in Series C funding, nearly tripling its valuation to $3.8 billion, as the AI drug discovery company signs licensing agreements with Pfizer Inc., Eli Lilly …
Google DeepMind and Isomorphic Labs have announced a joint initiative on bioresilience, using AI to predict and defend against biological threats, building on AlphaFold technology. Isomorphic Labs, fo…
Chai Discovery raised $400 million in a Series C round led by Index Ventures, tripling its valuation to $3.8 billion in seven months as the AI drug discovery startup's generative models are deployed a…
OpenAI researcher Miles Wang is in advanced talks to launch an AI drug discovery startup at a $2 billion valuation, with Lightspeed Venture Partners reportedly leading a $200 million round, according …
Chai Discovery has raised $400 million in a Series C round at a $3.8 billion valuation, tripling its valuation in seven months. The OpenAI-backed drug discovery startup, founded in 2024, builds AI mod…
OpenAI-backed Chai Discovery closed a $400 million funding round at a $3.8 billion valuation on July 14, tripling its price tag in seven months. The Index Ventures-led round positions the company as A…